Enterin, Inc is a pioneering pharmaceutical company based in Philadelphia, PA, with a groundbreaking mission to develop a revolutionary drug that repairs the dysfunctional gut-brain axis in patients suffering from neurodegenerative diseases. Their lead molecule, ENT-01, has shown promising results in preclinical models of Parkinson's Disease by displacing -synuclein aggregates and restoring normal signaling between the gut and the brain.
With recent success in meeting its primary endpoint in a Phase 2b study for Parkinson's Disease patients, Enterin's clinical data suggests that repairing the gut-brain axis can significantly enhance the quality of life for individuals affected by Parkinson's Disease and other neurodegenerative conditions, by addressing multiple non-motor symptoms. Driven by a vision of providing new hope against Parkinson's, autism, and other neurodegenerative diseases, Enterin is at the forefront of scientific research and development in this field.
Generated from the website